WuXi ATU Wins Tech Disruptor at the Advanced Therapies Awards 2023!
 

23 January 2023 – Miami. WuXi Advanced Therapies (WuXi ATU) received the 2023 Manufacturing Tech Disruptor of the Year Award, presented during Advanced Therapies Week (ATW). We received this award for our innovative transfection-free TESSA^TM(Tetracycline-Enabled Self-Silencing Adenovirus) technology for scalable manufacture of adeno-associated virus (AAV) vectors.

The Manufacturing Tech Disruptor award honors companies that have helped improve and simplify the cell and gene therapy manufacturing process through innovative new technology. 37 different companies and research institutes submitted applications, demonstrating the importance of manufacturing to the advanced therapies community.

"We are very honored to receive this accolade", said Dr. David Chang, Chief Executive Officer of WuXi ATU, "AAV vectors are commonly used to deliver gene therapies, with the potential for clinical trial candidates to treat life-altering diseases like hemophila B. With the growing demand for AAV vectors, processes for efficient large-scale production have become critical but reliance on plasmids creates bottlenecks for manufacture. Our plasmid-free TESSA^TM technology has the potential to significantly improve AAV yields and particle quality, reducing cost of goods and benefiting innovation in the cell and gene therapy industry and enabling our global customers."

"We really right now are trying to make sure this technology is being adopted by the industry. New technology takes a long time to make it to the mainstream, so our intention is to get the customer to experience TESSA^TMas soon as possible. We believe that once a customer has evaluated TESSA^TM they will start to choose it over the current standard of transient transfection." said Dr. David Chang.
 

WuXi ATU CEO Dr.David Chang (Second on the right) and team

As a new generation of innovation-driven CTDMO, WuXi ATU will continue to "Put Customers First", working to enable the cell and gene therapy industry through continued technological and production process innovation.

About TESSA^TM
 

TESSA^TM(Tetracycline-Enabled Self-Silencing Adenovirus) technology is a state-of-the-art novel process for transfection-free, scalable manufacture of AAV vectors at Good Manufacturing Practice (GMP) grade. Developed by OXGENE, a WuXi Advanced Therapies company, TESSA^TMwill expedite AAV manufacturing and significantly reduce the cost for manufacturing cell and gene therapies, enabling global customers to deliver more accessible ground-breaking therapeutics to patients as quickly as possible.

Up to now, TESSA^TM technology has obtained 28 international patents, and has reached cooperation with many companies or institutions around the world. WuXi Advanced Therapies and A*STAR’s Bioprocessing Technology Institute (BTI) announced a new partnership to bring TESSA^TMtechnology to the Asia-Pacific region on 28 April 2022. WuXi Advanced Therapies announced a licensing agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson ("Janssen") in August 2022. This new technology is attracting increasing attention and evaluation from biotechnology companies and large pharmaceutical companies. By the end of September 2022, 38 TESSA^TM projects are under customer evaluation, including 6 major biotech/pharmaceutical companies.

If you have any cooperation needs, please contact:

+86（021）3718 1888

info_ATU@wuxiapptec.com

About WuXi Advanced Therapies (WuXi ATU)

As the advanced therapies business unit of WuXi AppTec, WuXi Advanced Therapies is a Contract Testing, Development and Manufacturing Organization (CTDMO) that offers integrated platforms to transform the discovery, development, testing, manufacturing, and commercialization of cell and gene therapies. Our services and solutions accelerate time to market and support customer programs around the world. For more information, please visit https://www.advancedtherapies.com